Opus Genetics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Opus Genetics (IRD).

Price Target Range — 8 Quarters

Analyst Consensus — 16 Analysts

1S.Buy

15Buy

Consensus RatingBuy# Analysts16Avg. Consensus PT$12Upside to Avg. PT+239.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 22, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$16
Oct 16, 2026	Citizens	Jonathan Wolleben	Maintained	Market Outperform	$17
Oct 6, 2026	Jones Trading	—	PT Raise	Buy	$10→$17
Oct 2, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$16
Sep 10, 2026	Wedbush	Yun Zhong	PT Raise	Outperform	$10→$13
Sep 9, 2026	Chardan Capital	Andreas Argyrides	PT Raise	Buy	$13
Sep 9, 2026	Oppenheimer	Andreas Argyrides	PT Raise	Outperform	$10→$20
Sep 9, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$8
Sep 9, 2026	BTIG	Thomas Shrader	Maintained	Buy	$12
Aug 7, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$10→$9
Jul 29, 2026	TD Cowen	Ritu Baral	Initiate	Buy	—
Jul 6, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$13
Jul 6, 2026	BTIG	Thomas Shrader	Maintained	Buy	$12
Jun 18, 2026	Chardan Capital	Andreas Argyrides	PT Raise	Buy	$11→$13
Jun 17, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$8
Jun 16, 2026	BTIG	Thomas Shrader	Maintained	Buy	$12
Jun 15, 2026	Citizens	Jonathan Wolleben	Maintained	Market Outperform	$11
Jun 4, 2026	Guggenheim	Debjit Chattopadhyay	Initiate	Buy	$16
May 21, 2026	Leerink Partners	Lili Nsongo	Initiate	Outperform	$10
May 13, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$12→$11

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target

Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform and maintains $17 price target.

Benzinga Newsdesk

PRO
Jones Trading Maintains Buy on Opus Genetics, Raises Price Target to $17

Jones Trading maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $10 to $17.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13

Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

BTIG analyst Thomas Shrader reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $12 price target.

Benzinga Newsdesk

Opus Genetics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Opus Genetics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target

PRO
Jones Trading Maintains Buy on Opus Genetics, Raises Price Target to $17

PRO
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13

PRO
Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

PRO
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

PRO
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

People Also Watch

People Also Watch

Opus Genetics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Opus Genetics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target

PROJones Trading Maintains Buy on Opus Genetics, Raises Price Target to $17

PROWedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13

PROOppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

PROHC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

PROBTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

People Also Watch

People Also Watch

PRO
Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target

PRO
Jones Trading Maintains Buy on Opus Genetics, Raises Price Target to $17

PRO
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13

PRO
Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

PRO
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

PRO
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target